Communiqués ReShape Lifesciences Inc.

Actions

RSLS

US76090R2004

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,1916 ^USD	-3,23%		-1,89%	-23,27%

15/05	ReShape Lifesciences Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
15/05	Transcript : ReShape Lifesciences Inc., Q1 2024 Earnings Call, May 15, 2024

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update	15/05	AQ
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update	14/05	AQ
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update	01/04	AQ
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System	28/03	AQ
ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX	04/03	AQ
ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX	22/02	AQ
ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX	24/01	AQ
ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex	21/12	AQ
ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives	20/12	AQ
ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX	12/12	AQ
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds	21/11	AQ
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan	08/11	AQ
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update	06/11	AQ
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering	29/09/23	AQ
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI	22/09/23	AQ
ReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon System	21/09/23	AQ
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System	19/09/23	AQ
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device	14/09/23	AQ
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2023 Financial Results and Provides Corporate Update	07/08/23	AQ
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2023 and Provide Corporate Update	03/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ReShape Lifesciences Inc.

Actions

RSLS

US76090R2004

Communiqués

Filtres